Plant Name: Lithospermum erythrorhizon
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| GPBAR1; FFAR1; FFAR4; | |
| PTPN1; PTPN2; PTPRF; ACP1; CDC25B; | |
| PLA2G1B; FAAH; TDP1; RECQL; TERT; HPGD; HSD11B1; HSD17B10; AKR1B10; ALOX15; ALDH1A1; SOAT1; POLB; | |
| MAPK1; | |
| CA2; CA12; CA1; CA9; CA3; CA5A; CA7; CA14; CA5B; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| RORC; | |
| NR1H4; | |
| MMP1; MMP2; MMP9; | |
| TLR2; | |
| HIF1A; TP53; NFKB1; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; HSP90AA1; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | SOAT1 | Acyl coenzyme A:cholesterol acyltransferase 1 | P35610 | CHEMBL2782 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HSP90AA1 | Heat shock protein HSP 90-alpha | P07900 | CHEMBL3880 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 9.854E-14 | 2.384E-10 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, NR1H4, PPARA, PPARD, PPARG, PTPN1, RORC, TP53 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 5.160E-08 | 2.881E-05 | FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 3.528E-07 | 1.536E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.106E-07 | 2.035E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 5.141E-07 | 2.035E-04 | HPGD, MMP2, MMP9, TERT |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 7.047E-07 | 2.646E-04 | AKR1B10, CYP1A2, CYP2D6, CYP3A4, HSD11B1, NR1H4, PPARD, SOAT1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.831E-07 | 2.954E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 9.052E-07 | 2.954E-04 | NR1H4, PPARA, PPARD, PPARG, RORC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.829E-26 | 1.922E-21 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.143E-06 | 1.104E-03 | FABP3, FFAR1, NR1H4, PPARG, TLR2 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.545E-06 | 1.372E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0046903; secretion | 1.034E-05 | 2.322E-03 | CA2, CA9, FABP5, FFAR1, FFAR4, HIF1A, HSP90AA1, MAPK1, MMP9, NFKB1, NR1H4, PLA2G1B, TLR2 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 1.180E-05 | 2.486E-03 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.500E-05 | 2.943E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.646E-05 | 3.200E-03 | HIF1A, MMP1, MMP2, MMP9, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 1.928E-05 | 3.537E-03 | ALDH1A1, CYP3A4, FFAR1, FFAR4, HIF1A, HSD11B1, NFKB1, NR1H4, PPARD |
| BP | GO:0065007; biological regulation | GO:0055088; lipid homeostasis | 1.969E-05 | 3.544E-03 | FABP3, FABP4, NR1H4, PPARG, SOAT1 |
| BP | GO:0008152; metabolic process | GO:0019369; arachidonic acid metabolic process | 2.069E-05 | 3.663E-03 | ALOX15, CYP1A2, CYP2D6, FAAH |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.653E-05 | 4.344E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.653E-05 | 4.344E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 2.653E-05 | 4.344E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 2.653E-05 | 4.344E-03 | GPBAR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 3.124E-05 | 5.001E-03 | AKR1B10, ALDH1A1, ALOX15, CYP3A4, HIF1A, NR1H4, PPARD, SOAT1 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.288E-05 | 5.188E-03 | POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 3.799E-05 | 5.909E-03 | HIF1A, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.360E-05 | 6.593E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 4.400E-05 | 6.608E-03 | NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 5.164E-05 | 7.538E-03 | HIF1A, NFKB1, PPARA, PTPN2 |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 5.164E-05 | 7.538E-03 | FFAR1, HIF1A, NR1H4, PPARD |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 5.296E-05 | 7.538E-03 | PTPN1, PTPN2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.296E-05 | 7.538E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 5.449E-05 | 7.655E-03 | CA2, CA9, CYP1A2, HPGD, MAPK1, NFKB1, PPARG, RORC, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 5.638E-05 | 7.821E-03 | HIF1A, PPARD, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.847E-05 | 8.008E-03 | CA2, CA7, HIF1A, MAPK1, NR1H4, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 6.055E-05 | 8.212E-03 | FABP3, PLA2G1B, PPARA, PPARG, TLR2 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 6.825E-05 | 8.900E-03 | MMP1, MMP2, MMP9, PLA2G1B |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.649E-19 | 5.062E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.291E-18 | 3.082E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.437E-25 | 8.644E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.207E-11 | 1.754E-09 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.894E-07 | 7.527E-06 | HSP90AA1; MMP1; MMP2; MAPK1; PPARG; HIF1A; TP53; MMP9; NFKB1; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.190E-07 | 6.306E-06 | MMP1; MMP2; MAPK1; MMP9; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.432E-06 | 4.555E-05 | PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.649E-05 | 7.020E-04 | MMP2; MAPK1; TP53; HIF1A; MMP9; TLR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 6.496E-05 | 1.148E-03 | MAPK1; TP53; MMP9; NFKB1; TLR2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.970E-05 | 1.148E-03 | HSD11B1; CYP2D6; CYP1A2; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.297E-05 | 1.148E-03 | PTPN1; MAPK1; ACP1; PTPRF |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.294E-04 | 1.870E-03 | HSP90AA1; MAPK1; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.952E-04 | 2.388E-03 | HSP90AA1; MMP2; MAPK1; MMP9 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.740E-04 | 2.305E-03 | HPGD; PPARG; TP53; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.824E-04 | 3.207E-03 | PTPN1; PPARA; NFKB1; PTPRF |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 8.016E-05 | 1.275E-03 | MAPK1; PPARG; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.005E-04 | 5.633E-03 | MAPK1; PPARA; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.279E-04 | 6.092E-03 | LMNA; MAPK1; TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 8.557E-04 | 6.431E-03 | MAPK1; MAPT; TP53; NFKB1; CDC25B |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.060E-04 | 5.633E-03 | MAPK1; NFKB1; PPARD |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.060E-04 | 5.633E-03 | HSP90AA1; MAPK1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.303E-04 | 6.431E-03 | MAPK1; TP53; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 8.898E-04 | 6.431E-03 | RORC; NFKB1; TLR2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.377E-04 | 5.633E-03 | HSD11B1; CYP1A2; CYP3A4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.682E-03 | 9.221E-03 | MAPK1; TP53; MMP9; NFKB1; CDC25B |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.898E-04 | 6.431E-03 | CYP1A2; ALDH1A1; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 9.719E-04 | 6.439E-03 | MAPK1; TP53; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.246E-03 | 7.078E-03 | MAPK1; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.059E-03 | 6.733E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.246E-03 | 7.078E-03 | MAPK1; NFKB1; TLR2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.060E-03 | 1.352E-02 | HSP90AA1; MAPK1; TP53; NFKB1; TLR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.653E-03 | 1.278E-02 | MAPK1; PPARA; NFKB1; TSHR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.952E-03 | 1.341E-02 | POLB; MAPK1; TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.150E-03 | 7.033E-03 | CA2; NR1H4; CYP3A4 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.573E-03 | 1.278E-02 | PPARG; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.154E-03 | 1.355E-02 | MMP2; MAPK1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.896E-03 | 1.341E-02 | HSP90AA1; MAPK1; CDC25B |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.742E-03 | 9.234E-03 | HSD11B1; CYP1A2; CYP3A4 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.333E-03 | 1.395E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.614E-03 | 1.436E-02 | MAPK1; NFKB1; TLR2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.010E-03 | 1.555E-02 | MAPK1; MMP9; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.425E-03 | 1.396E-02 | MAPK1; NFKB1; TLR2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.217E-03 | 1.597E-02 | CYP2D6; ALOX15; MAPK1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.879E-03 | 1.763E-02 | MAPK1; TP53; HIF1A |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.879E-03 | 1.763E-02 | MAPK1; NFKB1; TLR2 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 6.653E-03 | 2.160E-02 | POLB; TERT; TP53; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.112E-03 | 1.767E-02 | MAPK1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.112E-03 | 1.767E-02 | MAPK1; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 6.655E-03 | 2.160E-02 | MAPK1; PPARG; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.225E-03 | 2.297E-02 | TP53; NFKB1; TLR2 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 7.670E-03 | 2.391E-02 | PTPN1; MAPK1; PTPRF |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.282E-02 | 3.639E-02 | MAPK1; MAPT; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.495E-02 | 3.860E-02 | MAPK1; NFKB1; TLR2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.656E-02 | 4.051E-02 | TP53; NFKB1; TLR2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.151E-02 | 3.328E-02 | FABP4; TSHR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.314E-02 | 3.664E-02 | MAPK1; HIF1A |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.987E-03 | 3.054E-02 | MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.151E-02 | 3.328E-02 | MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.398E-02 | 3.768E-02 | MAPK1; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.807E-02 | 4.288E-02 | MAPK1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.904E-02 | 4.388E-02 | MAPK1; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.855E-02 | 4.338E-02 | MAPK1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.529E-02 | 3.860E-02 | MAPK1; TP53 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.112E-02 | 3.328E-02 | NFKB1; TLR2 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.574E-02 | 3.911E-02 | MAPK1; HIF1A |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.759E-02 | 4.239E-02 | PPARA; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.003E-02 | 4.550E-02 | MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.398E-02 | 3.768E-02 | PLA2G1B; ALOX15 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.529E-02 | 3.860E-02 | MAPK1; NFKB1 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 6.303E-03 | 2.132E-02 | FABP2; PLA2G1B |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.011E-03 | 1.031E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.442E-02 | 3.821E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Dyslipidemia | NA | PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; HSP90AA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; FFAR1; PPARD; NFKB1; PPARG; PPARG |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; PLA2G1B |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT; MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; HSP90AA1; HSP90AA1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; HSP90AA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Refractory hematological malignancies | NA | HSP90AA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; HSP90AA1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; FAAH |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; FFAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; PPARD; PPARD; PPARG |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; FFAR1; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; PPARD |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; CA9; MAPK1; MMP9; NFKB1; TLR2; MMP2; HSP90AA1; CDC25B |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9; MAPK1; MMP9; TLR2; MMP2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; TERT; HSP90AA1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; TERT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; PLA2G1B |